PTX Acquires Worldwide License for Cancer Biomarker p27
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Later from Prescient Therapeutics
- Appendix 4C - quarterly
- Appointment of Managing Director to Drive Cancer Programs
- Co-X-Gene Development Pipeline
- Disclosure Document
- VHL completes Pathway acquisiton, appoints new director
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics